Introduction {#s1}
============

Genome-wide association (GWA) studies of colorectal cancer (CRC) have so far identified 14 common, low-risk susceptibility variants [@pgen.1002105-Houlston1]. Of these 14 variants, 3 are close to loci that are secreted members of the bone morphogenetic protein (BMP) signalling pathway: *GREM1* (rs4779584); *BMP4* (rs4444235); and *BMP2* (rs961253). In the colon, GREM1 is one of several BMP antagonists produced by sub-epithelial myofibroblasts (ISEMFs). GREM1 binds to and inactivates the ligands BMP2 and BMP4 that are primarily produced by inter-cryptal stromal cells.

Our GWA studies have utilised a primary phase of genome-wide typing of tagging single nucleotide polymorphisms (tagSNPs), followed by larger validation phases of those SNPs with the strongest signals of association. We have previously used relatively stringent statistical thresholds to take SNPs forward into the final validation phases [@pgen.1002105-Houlston1]. Whilst such a design has been cost-effective, the use of a lower threshold may have led to the discovery of more CRC SNPs, albeit at the cost of a relatively high type I error rate. One means of reducing false positives might be to select SNPs using a less stringent threshold where there is *a priori* evidence for candidacy. We reasoned that the best candidate loci were those already identified as harbouring CRC risk alleles. Of those 14 loci, we prioritised *GREM1*, *BMP2* and *BMP4* for further analysis owing to their strongly-related functions.

The GWA studies had identified a single tagSNP associated with CRC risk close to each of *GREM1*, *BMP2* and *BMP4* [@pgen.1002105-Houlston1]. Examination of the regions around these genes in public databases such as HapMap (<http://www.hapmap.org/>) showed in all cases that the coding sequence and predicted surrounding regulatory regions were present within more than one linkage disequilibrium (LD) block. For each of the 3 genes, therefore, it was possible that there were additional genetic determinants of CRC risk, independent of the already-identified SNPs. We proceeded to test this hypothesis in large sets of CRC cases and controls of European origin.

Results {#s2}
=======

The rs4779584 CRC signal results from two independent SNPs close to *GREM1* {#s2a}
---------------------------------------------------------------------------

In order to refine the location of CRC-associated functional variation close to the *GREM1*, *BMP4* and *BMP2* loci, we genotyped 442 SNPs close to rs4779584, rs4444235 and rs961253 in 4,878 CRC cases and 4,914 controls from the UK2 and Scotland2 sample sets and imputed other SNPs within these regions. No significant localisation of a functional variant was achieved for rs4444235 or rs961253 ([Figure S1](#pgen.1002105.s001){ref-type="supplementary-material"}), but at *GREM1*, rs16969681 (chr15:30,780,403 bases) had a notably stronger signal of association than rs4779584 (pairwise LD: r^2^ = 0.18, D′ = 0.70) ([Figure 1](#pgen-1002105-g001){ref-type="fig"} and [Figure S2](#pgen.1002105.s002){ref-type="supplementary-material"}). We genotyped rs16969681 in additional independent CRC case-control series (UK1, UK4, VQ58, Helsinki, Cambridge and EPICOLON; see [Methods](#s4){ref-type="sec"}). After combined analysis, a significant association between the minor allele at rs16969681 and CRC risk was seen (*P* = 5.33×10^−8^; [Table 1](#pgen-1002105-t001){ref-type="table"}). Unconditional logistic regression analysis, incorporating sample series as a co-variate, showed that rs16969681 was more strongly associated with CRC than rs4779584, but that the signals were non-independent (for rs16969681, OR = 1.16, 95% CI 1.07--1.25, *P* = 1.91×10^−4^; for rs4779584, OR = 1.08, 95% CI 1.02--1.14, *P* = 5.27×10^−3^). Akaike information criteria metrics for rs16969681 and rs4779584 respectively were 25608 and 25922, consistent with a superior fit of the risk model incorporating the former SNP. Intriguingly, we found that rs16969681 maps to a site of open chromatin in *GREM1*-expressing CRC cell lines, raising the possibility that it may be directly functional ([Figure S3](#pgen.1002105.s003){ref-type="supplementary-material"}).

![Fine mapping around the known CRC risk SNP close to *GREM1* (15q13.3).\
Results for meta-analysis of UK2 and Scotland2 are shown. Both significance of association (−log~10~(P)) and effect size (β) are presented. The original CRC-associated tagSNPs are shown in blue. The SNP with the clearly strongest association signal is the genotyped SNP rs16969681.](pgen.1002105.g001){#pgen-1002105-g001}
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###### Genotype counts and statistics of association at rs16969681, rs11632715, and rs4779584.

![](pgen.1002105.t001){#pgen-1002105-t001-1}

                                       Sample series               Case genotypes                Control genotypes                                Odds ratio
  ----------------------------------- --------------- ----------- ---------------- ----- ------ ------------------- ----- ------ ------- ------- ------------
  rs16969681                                 1            UK2            29         500   2335          28           399   2428   0.097   0.080     1.247
  z = 5.44                                   2         Scotland2         16         337   1653          10           293   1754   0.092   0.076     1.230
  P~overall~ = 5.33×10^−8^                   3            UK1            12         183   746            4           145   773    0.110   0.083     1.366
  OR = 1.181                                 4           VQNBS           8          235   1074          26           491   2418   0.095   0.093     1.033
  95%CI 1.113--1.254                         5         EPICOLON          13         313   1234          14           229   1025   0.109   0.101     1.081
  P~het~ = 0.013, I2 = 60.8%                 6         Helsinki          14         189   742            8           104   726    0.115   0.072     1.682
                                             7            UK4            6          95    482            6           180   862    0.092   0.092     1.002
  P~replicationphase~ = 2.73×10^−4^          8         Cambridge         21         370   1852          41           279   1818   0.092   0.084     1.097

                                                 TT    TC     CC    TT    TC     CC    freqT(cases)   freqT(controls)  
  ---------------------------- ---- ----------- ----- ----- ------ ----- ----- ------ -------------- ----------------- -------
  rs4779584                     1       UK2      155   934   1762   102   857   1858      0.218            0.188        1.203
  z = 6.30                      2    Scotland2   84    603   1276   72    608   1332      0.196            0.187        1.063
  P~overall~ = 2.98×10^−10^     3       UK1      52    316   533    30    288   611       0.233            0.187        1.319
  OR = 1.145                    4      VQNBS     81    564   1155   102   797   1601      0.202            0.200        1.009
  95%CI 1.098--1.195            5    EPICOLON    61    434   878    51    396   934       0.202            0.180        1.154
  P~het~ = 0.056, I2 = 45.8%    6    Helsinki    88    362   378    69    352   418       0.325            0.292        1.167
                                7       UK4      33    174   361    27    241   426       0.211            0.213        0.992
                                8    Scotland1   55    331   591    39    286   676       0.226            0.182        1.312
                                9      CCFR      58    412   716    32    319   647       0.223            0.192        1.206
                                10   Australia   22    149   269    17    136   285       0.219            0.194        1.167

                                                        AA     AG    GG    AA     AG    GG    freqA(cases)   freqA(controls)  
  ----------------------------------- ---- ----------- ----- ------ ----- ----- ------ ----- -------------- ----------------- ---------
  rs11632715                           1       UK2      719   1415   718   600   1450   768      0.500            0.470         1.128
  z = 6.34                             2    Scotland2   475   999    532   438   1040   579      0.486            0.466         1.084
  P~overall~ = 2.30×10^−10^            3       UK1      244   469    207   222   457    250      0.520            0.485         1.151
  OR = 1.116                           4      VQNBS     446   913    440   567   1252   679      0.502            0.478         1.101
  95%CI 1.079--1.155                   5    EPICOLON    308   684    401   238   651    378      0.467            0.445         1.092
  P~het~ = 0.997, I2 = 0.0%            6    Helsinki    182   488    272   150   409    276      0.452            0.425         1.119
                                       7       UK4      150   281    141   222   534    285      0.508            0.470        fs1.165
  P~replicationphase~ = 1.79×10^−7^    8    Scotland1   238   486    256   219   496    287      0.491            0.466         1.104
                                       9      CCFR      286   592    311   202   510    287      0.489            0.457         1.137
                                       10   Australia   106   226    105   88    231    119      0.501            0.465         1.158

All data sets in which rs16969681 and/or rs11632715 were genotyped are shown. The sample sets genotyped for the SNPs near *GREM1* are overlapping, but non-identical, largely because rs11632715 and rs4779584 (but not rs16969681) are present on the proprietary Illumina genome-wide arrays, and also because the Cambridge data set was additionally genotyped for rs16969681. In addition to the overall association test statistics, the P value for the replication phase (excluding UK2 and Scotland2) is shown for rs16969681 and rs11632715. Although there is considerable overlap, the sample sets genotyped here differ somewhat from those typed for the *BMP2* and *BMP4* SNPs. These differences result entirely from sample and data availability and practical issues of genotyping, including the following: GWAS data but not samples were available from some data sets, so that SNPs such as rs16969681 could not be genotyped in those sample sets; the 1958 Birth Cohort samples were not available at the time of genotyping rs16969681; and for some sample sets, DNA quantity was limiting.

Haplotype risk analysis ([Table S2](#pgen.1002105.s008){ref-type="supplementary-material"}) provided evidence that rs16969681 alleles do not capture all the CRC risk associated with rs4779584. In brief, data from UK2 and Scotland2 showed that the risk alleles at rs16969681 and rs4779584 were defined by a TGGTC haplotype at rs16969681-rs16969862-rs12594722-rs4779584-rs9888701. The TT rs16969681-rs4779584 haplotype was at a frequency of 0.063 in cases and 0.052 in controls (*P* = 6.29×10^−5^). However, there appeared to be a residual effect of the T allele at rs4779584, since there was also an elevated risk associated with the CT rs16969681-rs4779584 haplotype (*P* = 0.026).

We therefore tested the hypothesis that rs4779584 tags two independent risk SNPs at *GREM1*. We used reverse stepwise logistic regression to search the set of *GREM1* SNPs genotyped in the UK2 and Scotland2 samples ([Table S1](#pgen.1002105.s007){ref-type="supplementary-material"}) for associations that were independent of rs16969681 genotype and that captured the residual rs4779584 signal. This analysis led to elimination of rs4779584 from the regression model and identification of a model in which only rs16969681 (*P* = 1.04×10^−4^) and another SNP, rs11632715 (*P* = 1.00×10^−3^), produced independent signals. rs11632715 (chr15:30,791,539) is in low LD with rs16969681 (r^2^ = 0.009, D′ = 0.31) and modest LD with rs4779584 (r^2^ = 0.18, D′ = 0.90; [Figure S2](#pgen.1002105.s002){ref-type="supplementary-material"}). Through genotyping of additional case-control series, we showed that rs11632715 was significantly associated with CRC risk (*P* = 2.30×10^−10^; [Table 1](#pgen-1002105-t001){ref-type="table"}). Unconditional logistic regression in the 21,139 samples typed for both rs11632715 and rs16969681 provided confirmatory evidence of the independence of the signals (for rs16969681, *P* = 1.84×10^−6^ and for rs11632715, *P* = 6.36×10^−7^); these associations were of very similar magnitude to those obtained when each SNP was analysed individually in those sample sets ([Figure S2](#pgen.1002105.s002){ref-type="supplementary-material"}). Incorporation of rs4779584 into the logistic regression model showed that this SNP had a weaker effect than that of either rs16969681 or rs11632715 and did not significantly improve the model fit ([Table S3](#pgen.1002105.s009){ref-type="supplementary-material"}). Inspection of the region containing rs4779584, rs16969681 and rs11632715 ([Figure S2](#pgen.1002105.s002){ref-type="supplementary-material"}) showed that rs4779584 lay within a recombination hotspot. This finding was consistent with our discovery that rs4779584 tags two independent functional variants that are, in turn, tagged by rs16969681 and rs11632715.

Identification of additional, independent CRC susceptibility SNPs near *BMP4* and *BMP2* {#s2b}
----------------------------------------------------------------------------------------

The regions analysed for fine mapping encompassed only a minority of the transcribed and flanking regions of *GREM1*, *BMP4* and *BMP2*. We therefore tested for further independent CRC-associated SNPs around these loci ([Table S4](#pgen.1002105.s010){ref-type="supplementary-material"}) by undertaking a pooled analysis of data from 5 CRC GWA studies (UK1, Scotland1, VQ58, CCFR, Australia) and from the UK2 and Scotland2 samples that had been genotyped at 55,000 SNPs with the strongest evidence of association from meta-analysis of UK1 and Scotland1 ([Figure S4](#pgen.1002105.s004){ref-type="supplementary-material"}) [@pgen.1002105-Houlston1]. Since each of the 7 sample sets had been genotyped using different, but overlapping, SNP panels, we performed the combined analysis irrespective of the number of studies in which any SNP had been typed. [Figure 2](#pgen-1002105-g002){ref-type="fig"} shows the resulting signals of association from single SNP analysis in this discovery phase.

![Search for additional colorectal cancer susceptibility SNPs near *GREM1*, *BMP4*, and *BMP2*.\
Association signals from discovery phase around *GREM1*, *BMP4* and *BMP2* are shown. For *GREM1*, the labelled SNPs are highyl correlated tagSNPs originally reported as associated with CRC; these signals are non-independent. For *BMP4* and *BMP2*, the labelled SNPs are the original tagSNPs and the subsequently proven new signals at rs1957636 and rs4813802 respectively.](pgen.1002105.g002){#pgen-1002105-g002}

We prioritised SNPs for further assessment in the replication data sets if they passed two thresholds. First, we required SNPs to show association with CRC at *P*\<1×10^−4^ under the allelic or Cochran-Armitage tests; this was a less stringent threshold than that used in our previously-reported hypothesis-free GWA studies [@pgen.1002105-Houlston1], [@pgen.1002105-Tomlinson1], [@pgen.1002105-Houlston2], reflecting the fact that *GREM1*, *BMP4* and *BMP2* were strong candidate susceptibility genes. Four SNPs at *BMP4*, 3 at *BMP2* and 9 at *GREM1* fulfilled this criterion ([Figure 2](#pgen-1002105-g002){ref-type="fig"}). Second, since our aim was to test for novel, independent disease variants rather than to refine existing signals of association, we required that SNP genotypes were not correlated with each other or with previously identified risk SNPs (r^2^\<0.05, D′\<0.10). After applying these criteria, one SNP at *BMP4* (rs1957636) and one at *BMP2* (rs4813802) were retained for subsequent analyses.

rs1957636 and rs4813802 were then genotyped in the validation sample sets ([Figure S4](#pgen.1002105.s004){ref-type="supplementary-material"}), comprising 15,075 CRC cases and 13,296 controls from six independent European case-control series (COIN/NBS, UK3, UK4, Scotland3, Cambridge, Helsinki). After combined analysis, significant associations ([Table 2](#pgen-1002105-t002){ref-type="table"}) were shown for both rs1957636, *P* = 1.36×10^−9^ (OR = 1.08, 95% CI: 1.06--1.011, *P* ~het~ = 0.009, I^2^ = 54%) and rs4813802, *P* = 7.52×10^−11^ (OR = 1.09, 95% CI: 1.06--1.012, *P* ~het~ = 0.42, I^2^ = 3%). In case-only analysis, neither SNP showed any evidence of association with age or sex (*P*\>0.05, details not shown).

10.1371/journal.pgen.1002105.t002

###### Summary of individual SNP association analysis for rs4444235, rs1957636, rs961253, and rs4813802.

![](pgen.1002105.t002){#pgen-1002105-t002-2}

                                  Sample series               Case genotypes                 Control genotypes                                  OR
  ------------------------------ --------------- ----------- ---------------- ------ ------ ------------------- ------ ------ ------- ------- -------
  rs4444235                             1            UK1           247         441    233           184          470    274    0.508   0.452   1.252
  P~overall~ = 1.95×10^−11^             2         Scotland1        220         500    256           195          512    294    0.482   0.451   1.133
  OR = 1.091                            3            UK2           684         1407   761           639          1322   857    0.487   0.461   1.106
  95%CI 1.064--1.119                    4         Scotland2        449         1017   540           428          999    630    0.477   0.451   1.112
  P~het~ = 0.589, I2 = 0.0%             5           VQ58           410         886    503           603          1312   773    0.474   0.468   1.023
                                        6           CCFR           298         595    290           227          496    274    0.503   0.476   1.114
                                        7         Australia        108         208    124           76           233    129    0.482   0.439   1.186
  P~discovery~ = 1.61×10^−7^            8         Helsinki         202         459    272           150          405    273    0.462   0.426   1.161
                                        9         Cambridge        537         1083   618           519          1086   650    0.482   0.471   1.045
  P~replication~ = 1.56×10^−5^         10         COIN/NBS         510         1044   593           532          1246   722    0.481   0.462   1.078
                                       11            UK3           1828        3865   2012         1006          2116   1247   0.488   0.472   1.065
                                       12         Scotland3        268         554    305           432          1130   628    0.484   0.455   1.121
                                       13            UK4           127         306    141           210          544    288    0.488   0.463   1.107

                                                    AA     AG     GG    AA     AG     GG    freqA(cases)   freqA(controls)   1.06
  ------------------------------ ---- ----------- ------ ------ ------ ----- ------ ------ -------------- ----------------- -------
  rs1957636                       1       UK1      171    440    310    151   435    343       0.425            0.397        1.122
  P~overall~ = 1.36×10^−9^        2    Scotland1   172    484    320    148   499    354       0.424            0.397        1.118
  OR = 1.084                      3       UK2      475    1383   1002   457   1348   1044      0.408            0.397        1.046
  95%CI 1.056--1.112              4    Scotland2   365    964    677    324   971    761       0.422            0.394        1.125
  P~het~ = 0.009, I2 = 54.1%      5      VQ58      302    891    606    445   1303   941       0.416            0.408        1.032
                                  6      CCFR      206    594    386    142   486    370       0.424            0.386        1.173
                                  7    Australia    68    220    152    62    208    168       0.405            0.379        1.113
  P~discovery~ = 2.79×10^−5^      8    Helsinki    169    462    292    146   397    253       0.433            0.433        1.002
                                  9    Cambridge   364    1071   788    382   1053   765       0.405            0.413        0.966
  P~replication~ = 1.24×10^−5^    10   COIN/NBS    405    1087   690    320   1056   797       0.435            0.390        1.201
                                  11      UK3      1234   3443   2438   660   2076   1519      0.415            0.399        1.070
                                  12   Scotland3   223    601    448    326   1160   808       0.412            0.395        1.071
                                  13      UK4      128    274    182    159   485    400       0.454            0.385        1.329

                                                     AA     AC     CC    AA     AC     CC    freqA(cases)   freqA(controls)  
  ------------------------------- ---- ----------- ------ ------ ------ ----- ------ ------ -------------- ----------------- -------
  rs961253                         1       UK1      160    418    343    133   423    373       0.401            0.371        1.134
  P~overall~ = 4.45×10^−16^        2    Scotland1   151    460    366    127   468    406       0.390            0.361        1.133
  OR = 1.117                       3       UK2      418    1335   1099   351   1300   1167      0.381            0.355        1.115
  95%CI 1.088--1.148               4    Scotland2   300    939    767    265   898    894       0.384            0.347        1.171
  P~het~ = 0.379, I2 = 6.8%        5      VQ58      219    771    620    357   1249   1083      0.375            0.365        1.046
                                   6      CCFR      159    558    469    116   470    410       0.369            0.352        1.076
                                   7    Australia    63    218    159    58    193    187       0.391            0.353        1.178
  P~discovery~ = 1.29×10^−7^       8    Helsinki    115    408    418    72    335    407       0.339            0.294        1.230
                                   9    Cambridge   287    928    801    275   971    898       0.373            0.355        1.080
  P~replication~ = 4.97×10^−10^    10   COIN/NBS    305    1034   843    332   1171   997       0.377            0.367        1.042
                                   11      UK3      1073   3665   2913   551   1944   1823      0.380            0.353        1.124
                                   12   Scotland3   177    503    423    260   975    947       0.388            0.343        1.219
                                   13      UK4       95    271    204    147   474    422       0.404            0.368        1.165

                                                    GG     TG     TT    GG     TG     TT    freqG(cases)   freqG(controls)  
  ------------------------------ ---- ----------- ------ ------ ------ ----- ------ ------ -------------- ----------------- -------
  rs4813802                       1       UK1      141    425    350    130   398    393       0.386            0.357        1.131
  P~overall~ = 7.52×10^−11^       2    Scotland1   147    452    373    151   450    393       0.384            0.378        1.023
  OR = 1.093                      3       UK2      374    1299   1026   335   1294   1037      0.379            0.368        1.048
  95%CI 1.064--1.122              4    Scotland2   359    918    724    277   955    830       0.409            0.366        1.198
  P~het~ = 0.416, I2 = 3.1%       5      VQ58      268    832    694    351   1208   1131      0.381            0.355        1.120
                                  6      CCFR      176    546    460    112   445    436       0.380            0.337        1.206
                                  7    Australia    53    208    169    53    212    173       0.365            0.363        1.009
  P~discovery~ = 2.75×10^−7^      8    Helsinki    131    400    395    88    366    375       0.357            0.327        1.145
                                  9    Cambridge   280    992    707    284   1039   832       0.392            0.373        1.085
  P~replication~ = 3.47×10^−5^    10   COIN/NBS    313    982    818    327   1162   1012      0.381            0.363        1.078
                                  11      UK3      1037   3582   2969   544   2025   1751      0.373            0.360        1.055
                                  12   Scotland3   205    523    451    318   1043   878       0.396            0.375        1.091
                                  13      UK4       92    265    221    102   285    301       0.388            0.355        1.152

Results of allelic test of association in all sample sets are shown.

We used unconditional logistic regression, adjusting for sample series, to test the independence of the two pairs of SNPs at *BMP4* and at *BMP2*. In both cases, each signal remained independent, reflecting the existence of recombination hotspots between the pairs of SNPs at each locus ([Figure S5](#pgen.1002105.s005){ref-type="supplementary-material"} and [Figure S6](#pgen.1002105.s006){ref-type="supplementary-material"}). For rs4444235 and rs1957636, association *P*-values were respectively 2.09×10^−8^ (I^2^ = 47.7%) and 3.93×10^−10^ (I^2^ = 0%)). For rs961253 and rs4813802, *P*-values were 1.89×10^−15^ (I^2^ = 5%) and 4.65×10^−11^ (I^2^ = 5%)). Thus, all 4 SNPs represented independent signals of association with CRC. Further imputation around *BMP4* and *BMP2* provided no evidence for the alternative possibility that a single variant was tagged by the two SNPs in each region (details not shown).

Annotation of the regions around rs1957636 and rs4813802 {#s2c}
--------------------------------------------------------

rs1957636 (chr14: 53,629,768) is 136 kb upstream of the transcriptional start site of *BMP4*, 150 kb telomeric to the previously-identified CRC susceptibility SNP, rs4444235 (chr14:53,480,669), which is downstream of *BMP4*. There is a recombination hotspot at chr14:53,510,000 ([Figure S5](#pgen.1002105.s005){ref-type="supplementary-material"}) and LD between rs1957636 and rs4444235 is very weak (r^2^ = 0.004, D′ = 0.073 from UK1). rs1957636 is within a region of LD flanked by SNPs rs431669 (chr14:53,512,418) and rs10150369 (chr14:53,873,515). This region contains no known transcripts, and the nearest gene apart from *BMP4* is *CDKN3* (transcriptional start site, chr14:53,933,476). Using SNAP (<http://www.broadinstitute.org/mpg/snap/>) to search HapMap3 release 2 and 1000 Genomes Pilot 1, we identified 265 SNPs were in moderate or greater LD (r^2^\>0.20) with rs1957636 in Europeans. Of those SNPs, several mapped to sites of potential functional importance in *BMP4* transcription (H3K4Me1, H3K4Me3, DNAseI hypersensitivity, transcription factor ChIP-Seq), as evidenced by the ENCODE regulation tracks (<http://genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=171775907&c=chr14&g=wgEncodeReg>) of the UCSC Genome Browser. For example, rs12432287 (r^2^ = 0.60, D′ = 1.00 with rs1957636) and rs728425 (r^2^ = 0.69, D′ = 1.00) lie within a region of apparently high transcriptional regulatory activity at chr14:53,642,340--53,652,937. Another SNP, rs8011813 (r^2^ = 0.822, D′ = 0.811), maps within a similar region at chr14:53, 728, 957--53, 731, 647. Although none of the SNPs in the region around rs1957636 is the location of a reported eQTL (<http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/>), no studies relating transcription to SNP genotype have yet been undertaken in the colorectum.

rs4813802 maps to chr20:6,647,595, about 49 kb upstream of *BMP2* and 295 kb telomeric of the previously-identified *BMP2* CRC susceptibility SNP, rs961253 (chr20:6,352,281). There is very little LD between these two SNPs (r^2^ = 0.000, D′ = 0.017 from UK1) owing to a recombination hotspot at chr20:6,587,000 ([Figure S5](#pgen.1002105.s005){ref-type="supplementary-material"}). rs4813802 lies within a region of LD flanked by rs727689 (chr20:6,636,405) and rs6117401 (chr20:6,664,097). This region contains 3 spliced ESTs, BX107852, BG822004 and DB094697; none of these has any known functional role or homology to other human or non-human transcripts or genes. The nearest gene to rs4813802 apart from *BMP4* is *FERMT1* (transcriptional start site, chr20:6,052,191). From HapMap3 release 2 and 1000 Genomes Pilot 1, 29 SNPs were found to be in moderate or greater LD (r^2^\>0.20) with rs4813802 in Europeans. Of those SNPs, several in the region chr20:6,636,405--6,647,595 mapped to sites of potential functional importance in *BMP2* transcription. None of the SNPs in the area around rs4813802 is the location of a reported eQTL.

Gene-gene interactions and other SNPs near BMP pathway loci {#s2d}
-----------------------------------------------------------

Using a case-control logistic regression design, we searched for pairwise gene-gene interactions between 5 SNPs associated with CRC risk (rs4444235, rs1957636, rs961253, rs4813802 and rs4779584). Risks were additive and no evidence of epistasis was detected (*P*\>0.2 for all SNP pairs).

We also searched for evidence of CRC susceptibility alleles at tagSNPs close to other BMP pathway genes. Using the transcribed regions of flanking genes as boundaries, we identified 4,361 tagSNPs mapping to 37 BMP agonist, antagonist and receptor loci ([Table S5](#pgen.1002105.s011){ref-type="supplementary-material"}). However, we found no statistically significant evidence of associations with disease (*P*\>10^−3^ in all cases).

Discussion {#s3}
==========

We have identified two new CRC predisposition tagSNPs close to *BMP4* (rs1957636) and *BMP2* (rs4813802). To date, few other loci have been shown at stringent levels of significance to harbour more than one, independent cancer susceptibility variant. One notable exception is the locus proximal to *MYC* on chromosome 8q24.21 that contains multiple regions independently associated with the risk of prostate and other cancers [@pgen.1002105-AlOlama1]. Low-penetrance cancer predisposition loci are becoming increasingly hard to identify, owing to small effect sizes and/or low risk allele frequencies -- and a return to candidate gene-based approaches may become increasingly attractive. It is true that in the past, candidate gene approaches have generally been unsuccessful at identifying cancer risk loci, but it is now possible to make use of information, such as expression quantitative trait locus identification, that increasingly permits a more considered approach.

We have also found good evidence that the original CRC-associated SNP near *GREM1*, rs4779584 [@pgen.1002105-Jaeger1], tags two independent functional SNPs, represented by association signals at rs16969681 and rs11632715. This finding emphasises that genetic fine-mapping studies are valuable not only for detecting stronger association signals, but also for deconvoluting tagSNP associations that have arisen owing to independent correlation of the tagSNP with more than one functional SNP. The original rs4779584 tagSNP signal could be described as an example of "synthetic association", a term that has been used to describe a situation in which multiple, sometimes rare, variants underlie a tagSNP signal [@pgen.1002105-Dickson1], [@pgen.1002105-Wray1]. Synthetic association can explain some of the apparently missing heritability of complex diseases. Here, we estimate that the 6 SNPs close to the 3 BMP pathway genes contribute approximately 2% of the heritability of CRC, about double that estimated before this study.

Finally, our data provide evidence that *GREM1*, *BMP4* and *BMP2* are the targets of the functional variation in each region. Multiple, independently-acting variants close to these loci contribute to CRC risk. Perhaps unexpectedly, there are no detectable genetic interactions among these variants. If the downstream *SMAD* effectors that function within both the BMP and TGF-beta pathways are included, the components of BMP signalling involved in CRC risk might comprise up to 3 high-penetrance predisposition genes (*SMAD4*, *BMPR1A*, *GREM1*) and 8 low-penetrance variants at *GREM1*, *BMP4*, *BMP2*, *SMAD7* and *LAMA5* (tagged respectively by rs16969681 and rs11632715, rs4444235 and rs1957636, rs961253 and rs4813802, rs4939827, and rs4925386) [@pgen.1002105-Houlston1], [@pgen.1002105-Tomlinson1], [@pgen.1002105-Houlston2], [@pgen.1002105-Jaeger1], [@pgen.1002105-Broderick1], [@pgen.1002105-Howe1], [@pgen.1002105-Howe2], [@pgen.1002105-Jaeger2]. Collectively these data emphasise the potential importance of genetic variants in the BMP pathway for CRC predisposition.

Methods {#s4}
=======

Ethics statement {#s4a}
----------------

Collection of blood samples and clinico-pathological information from patients and controls was undertaken with informed consent and ethical review board approval in accordance with the tenets of the Declaration of Helsinki.

Overall strategy {#s4b}
----------------

The study had two main components: (i) refinement of existing GWAS signals at the *GREM1*, *BMP4* and *BMP2* loci using a dense genotyping and imputation approach in several thousand cases and controls previously used for GWAS validation; and (ii) a search for new, independent CRC tagSNPs at the same three loci using a less stringent threshold for validation than used previously, combined with multiple validation sample sets.

Discovery screen data sets {#s4c}
--------------------------

UK1 (CORGI) [@pgen.1002105-Houlston1] comprised 922 cases with colorectal neoplasia (47% male) ascertained through the Colorectal Tumour Gene Identification (CoRGI) consortium. All had at least one first-degree relative affected by CRC and one or more of the following phenotypes: CRC at age 75 or less; any colorectal adenoma (CRAd) at age 45 or less; ≥3 colorectal adenomas at age 75 or less; or a large (\>1 cm diameter) or aggressive (villous and/or severely dysplastic) adenoma at age 75 or less. The 929 controls (45% males) were spouses or partners unaffected by cancer and without a personal family history (to 2^nd^ degree relative level) of colorectal neoplasia. Known dominant polyposis syndromes, HNPCC/Lynch syndrome or bi-allelic *MYH* mutation carriers were excluded. All cases and controls were of white UK ethnic origin.

Scotland1 (COGS) [@pgen.1002105-Houlston1] included 980 CRC cases (51% male; mean age at diagnosis 49.6 years, SD±6.1) and 1,002 cancer-free population controls (51% male; mean age 51.0 years; SD±5.9). Cases were for early age at onset (age ≤55 years). Known dominant polyposis syndromes, HNPCC/Lynch syndrome or bi-allelic *MYH* mutation carriers were excluded. Control subjects were sampled from the Scottish population NHS registers, matched by age (±5 years), gender and area of residence within Scotland.

VQ58 comprised 1,832 CRC cases (1,099 males, mean age of diagnosis 62.5 years; SD±10.9) from the VICTOR [@pgen.1002105-Midgley1] and QUASAR2 ([www.octo-oxford.org.uk/alltrials/trials/q2.html](http://www.octo-oxford.org.uk/alltrials/trials/q2.html)) trials. There were 2,720 population control genotypes (1,391 males,) from the Wellcome Trust Case-Control Consortium 2 (WTCCC2) 1958 birth cohort (also known as the National Child Development Study), which included all births in England, Wales and Scotland during a single week in 1958 [@pgen.1002105-Power1].

The Colon Cancer Family Registry (CCFR) data set [@pgen.1002105-Newcomb1] comprised 1,332 familial CRC cases and 1,084 controls Colon Cancer Family Registry (Colon-CFR) (<http://epi.grants.cancer.gov/CFR/about_colon.html>). The cases were recently diagnosed CRC cases reported to population complete cancer registries in the USA (Puget Sound, Washington State) who were recruited by the Seattle Familial Colorectal Cancer Registry; in Canada (Ontario) who were recruited by the Ontario Familial Cancer Registry; and in Australia (Melbourne, Victoria) who were recruited by the Australasian Colorectal Cancer Family Study. Controls were population-based and for this analysis were restricted to those without a family history of colorectal cancer.

The Australian study [@pgen.1002105-Tie1] comprised 591 patients treated for CRC at the Royal Melbourne, Western and St Francis Xavier Cabrini Hospitals in Melbourne from 1999 to 2009. The 2,353 controls were derived from Queensland or Melbourne: for the former, the controls came from the Brisbane Twin Nevus Study [@pgen.1002105-Duffy1]; for the latter, individuals were participants in the Genes in Myopia study [@pgen.1002105-Baird1]. There was no overlap between the CFR and Australian data sets. Owing to potential residual ethnic heterogeneity within the Melbourne population, for the Australian cohort only we performed an additional screen to minimise heterogeneity after performing principal components analysis (PCA) to remove individuals who clustered with non-CEU individuals (see below). We achieved this by performing PCA on the Australian cases and controls without reference samples of known ancestry. We then paired each case with a control in a 1∶1 ratio based on a maximum separation of 0.050 using the first and second eigenvectors. All unpaired samples were excluded, leaving 441 cases and 441 controls in the study. The genomic inflation factor, λ~GC~, was 1.02 after this filtering.

UK2 (NSCCG) [@pgen.1002105-Houlston1] consisted of 2,854 CRC cases (58% male, mean age at diagnosis 59.3 years; SD±8.7) ascertained through two ongoing initiatives at the Institute of Cancer Research/Royal Marsden Hospital NHS Trust (RMHNHST) from 1999 onwards - The National Study of Colorectal Cancer Genetics (NSCCG) and the Royal Marsden Hospital Trust/Institute of Cancer Research Family History and DNA Registry. The 2,822 controls (41% males; mean age 59.8 years; SD±10.8) were the spouses or unrelated friends of patients with malignancies. None had a personal history of malignancy at time of ascertainment. All cases and controls had self-reported European ancestry, and there were no obvious differences in the demography of cases and controls in terms of place of residence within the UK.

Scotland2 (SOCCS) [@pgen.1002105-Houlston1] comprised 2,024 CRC cases (61% male; mean age at diagnosis 65.8 years, SD±8.4) and 2,092 population controls (60% males; mean age 67.9 years, SD±9.0) ascertained in Scotland. Cases were taken from an independent, prospective, incident CRC case series and aged \<80 years at diagnosis. Control subjects were population controls matched by age (±5 years), gender and area of residence within Scotland.

Replication data sets {#s4d}
---------------------

UK3 (NSCCG) [@pgen.1002105-Houlston1] comprised 7,912 CRC cases (65% male; mean age at diagnosis 59 years, SD±8.2) and 4,398 controls (40% male; mean age 62 years, SD±11.5) ascertained through NSCCG post-2005.

Scotland3 (SOCCS) [@pgen.1002105-Houlston1] comprised 1,145 CRC cases (50% male; mean age at diagnosis 53.2 years, SD±15.4) and 2,203 cancer-free population controls (47% male; mean age 51.8 years, SD±11.5). Controls were recruited as part of the Generation Scotland study.

UK4 (CORGI2BCD) [@pgen.1002105-Houlston1] consisted of 621 CRC cases (46% male; mean age at diagnosis 58.3 years; SD±14.1) and 1,121 cancer-free population or spouse controls (45% male; mean age 45.1 years, SD±15.9).

Cambridge/SEARCH consisted of 2,248 CRC cases (56% male; mean age at diagnosis 59.2 years, SD±8.1) and 2,209 controls (42% males; mean age 57.6 years; SD±15.1. Samples were ascertained through the SEARCH (Studies of Epidemiology and Risk Factors in Cancer Heredity, <http://www.cancerhelp.org.uk/trials/a-study-looking-at-genetic-causes-of-cancer>) study based in Cambridge, UK. Recruitment started in 2000; initial patient contact was though the general practitioner. Control samples were collected post-2003. Eligible individuals were sex- and frequency-matched in five-year age bands to cases.

The COIN samples [@pgen.1002105-Adams1] were 2,151 cases derived from the COIN and COIN-B clinical trials of metastatic CRC. Median age was 63 years. COIN cases were compared against genotypes from 2,501 population controls (1,237 males,) from the WTCCC2 National Blood Service (NBS) cohort (50% male; mean age at diagnosis 53.2 years, SD±15.4).

The Helsinki (FCCPS) study (<http://research.med.helsinki.fi/gsb/aaltonen/>) comprised 988 cases from a population-based collection centred on south-eastern Finland and 864 population controls from the same collection.

EPICOLON [@pgen.1002105-Abuli1] included 1,410 cases matched with the same number of controls collected in a prospective fashion from centres in Spain. Exclusion criteria were Mendelian CRC syndromes and a personal history of inflammatory bowel disease.

In all cases CRC was defined according to the ninth revision of the International Classification of Diseases (ICD) by codes 153--154 and all cases had pathologically proven adenocarcinomas.

Sample preparation and genotyping {#s4e}
---------------------------------

DNA was extracted from samples using conventional methods and quantified using PicoGreen (Invitrogen). The VQ, UK1, Scotland1 and Australia GWA cohorts were genotyped using Illumina Hap300, Hap370, or Hap550 arrays. 1958BC and NBS genotyping was performed as part of the WTCCC2 study on Hap1M arrays. The CCFR samples were genotyped using Illumina Hap1M or Hap1M-Duo arrays. In UK2 and Scotland2, genotyping was conducted using custom Illumina Infinium arrays according to the manufacturer\'s protocols. Some COIN SNPs were typed on custom Illumina Goldengate arrays. To ensure quality of genotyping, a series of duplicate samples was genotyped, resulting in 99.9% concordant calls in all cases.

Other genotyping was conducted using competitive allele-specific PCR KASPar chemistry (KBiosciences Ltd, Hertfordshire, UK), Taqman (Life Sciences, Carlsbad, California) or MassARRAY (Sequenom Inc., San Diego, USA). All primers, probes and conditions used are available on request. Genotyping quality control was tested using duplicate DNA samples within studies and SNP assays, together with direct sequencing of subsets of samples to confirm genotyping accuracy. For all SNPs, \>99% concordant results were obtained.

Quality control and sample exclusion {#s4f}
------------------------------------

We excluded SNPs from analysis if they failed one or more of the following thresholds: GenCall scores \<0.25; overall call rates \<95%; MAF\<0.01; departure from Hardy-Weinberg equilibrium (HWE) in controls at *P*\<10^−4^ or in cases at *P*\<10^−6^; outlying in terms of signal intensity or X∶Y ratio; discordance between duplicate samples; and, for SNPs with evidence of association, poor clustering on inspection of X∶Y plots.

We excluded individuals from analysis if they failed one or more of the following thresholds: duplication or cryptic relatedness to estimated identity by descent (IBD) \>6.25%; overall successfully genotyped SNPs \<95%; mismatch between predicted and reported gender; outliers in a plot of heterozygosity *versus* missingness; and evidence of non-white European ancestry by PCA-based analysis in comparison with HapMap samples (<http://hapmap.ncbi.nlm.nih.gov/>). We excluded 6 duplicate samples using PCA (see below) within the UK samples that had undergone analysis of over 200 SNPs (UK1, Scotland1, UK2, Scotland2, VQ, 1958BC, NBS, COIN). We excluded duplicates from other UK cohorts on the basis of names (or initials where release of names was not possible) and dates of birth. No duplicates were found from the CCFR or Australian sample sets.

To identify individuals who might have non-northern European ancestry, we merged our case and control data from all sample sets with the 60 European (CEU), 60 Nigerian (YRI), and 90 Japanese (JPT) and 90 Han Chinese (CHB) individuals from the International HapMap Project. For each pair of individuals, we calculated genome-wide identity-by-state distances based on markers shared between HapMap2 and our SNP panel, and used these as dissimilarity measures upon which to perform principal components analysis. Principal components analysis was performed using Eigenstrat/SmartPCA using CEU, YRI and HCB HapMap samples as reference. The first two principal components for each individual were plotted and any individual not present in the main CEU cluster (that is, \>5% of the PC distance from HapMap CEU cluster centroid) was excluded from subsequent analyses.

We had previously shown the adequacy of the case-control matching and possibility of differential genotyping of cases and controls using Q-Q plots of test statistics in STATA. The inflation factor λ~GC~ was calculated by dividing the mean of the lower 90% of the test statistics by the mean of the lower 90% of the expected values from a χ^2^ distribution with 1 d.f. Deviation of the genotype frequencies in the controls from those expected under HWE was assessed by χ^2^ test (1 d.f.), or Fisher\'s exact test where an expected cell count was \<5.

SNP selection and genotyping for fine mapping {#s4g}
---------------------------------------------

Regions selected for fine mapping were: chr15:30,733,560--30,802,752; chr14:53,430,973n 53,530,761; and chr20:6,292,730--6,402,661. These corresponded to the haplotype blocks and immediately flanking regions harbouring rs4779584, rs4444235, and rs961253. To define these haplotype blocks and the recombination hotspots harbouring these CRC-associated SNPs, we used Haploview and SequenceLDHot. From dbSNP (build 128), we selected all SNPs between the recombination hotspots flanking the haplotype block. All these SNPs were submitted to Illumina for assay design and those with a design score\>0.3 were genotyped on custom arrays in the UK2 and Scotland2 case-control series. In total, we genotyped 81, 42 and 60 SNPs in the 15q13.3, 14q22.2 and 20p12.3 regions respectively. A list of these SNPs is shown in [Table S1](#pgen.1002105.s007){ref-type="supplementary-material"}. Association statistics, using an additive model, were obtained with SNPTEST v2 ([www.stats.ox.ac.uk/\~marchini/software/gwas/snptest.html](http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html)). We used genotype data from the 1000 Genomes CEPH (<http://www.1000genomes.org/>) and HapMap3 CEPH and TSI samples ([www.hapmap.org/](http://www.hapmap.org/)) and the IMPUTE v2 software (<https://mathgen.stats.ox.ac.uk/impute/impute_v2.html>) to generate *in silico* genotypes at additional SNPs in all three regions. This imputation resulted in the addition of 74, 113 and 255 markers in the chromosome 15q13.3, 14q22.2 and 20p12.3 regions respectively (for details on imputed and genotyped markers see [Table S1](#pgen.1002105.s007){ref-type="supplementary-material"}). Association meta-analyses only included markers with proper_info scores \>0.5, imputed call rates per SNP \>0.9 and minor allele frequencies (MAFs) \>0.01. Meta-analyses of the two sample sets were carried out with Meta (<http://www.stats.ox.ac.uk/~jsliu/meta.html>) using the genotype probabilities from IMPUTE v2, where a SNP was not directly typed. To test for the presence of additional independent risk alleles in each region, we carried out logistic regression analysis within each region, both pairwise with the original tagSNP and then in a backwards analysis that included all SNPs with evidence of association in the meta-analysis at P\<5×10^−4^.

Statistical analysis {#s4h}
--------------------

Association between SNP genotype and disease status was primarily assessed in STATA v10 (<http://www.stata.com/>) and PLINK v1.07 (<http://pngu.mgh.harvard.edu/~purcell/plink/>) using allelic and Cochran-Armitage tests (both with 1df) respectively, or by Fisher\'s exact test where an expected cell count was \<5. Genotypic (2df), dominant (1df) and recessive (1df) tests were also performed. The risks associated with each SNP were estimated by allelic, heterozygous and homozygous odds ratios (ORs) using unconditional logistic regression, and associated 95% confidence intervals (CIs) were calculated.

Joint analysis of data generated from multiple phases was conducted using standard methods for combining raw data based on the Mantel-Haenszel method in STATA and PLINK. The reported meta-analysis statistics were derived from analysis of allele frequencies, and joint ORs and 95% CIs were calculated assuming fixed- and random-effects models. Tests of the significance of the pooled effect sizes were calculated using a standard normal distribution. Cochran\'s Q statistic to test for heterogeneity [@pgen.1002105-Petitti1] and the I^2^ statistic [@pgen.1002105-Higgins1] to quantify the proportion of the total variation due to heterogeneity were calculated. Large heterogeneity is typically defined as I^2^≥75%. Where significant heterogeneity was identified, results from the random effects model were reported. Alongside, we also performed meta-analysis based on allele dosage (0, 1, 2) and incorporated age and sex as co-variates. Although age and sex are associated with colorectal cancer risk, they were not associated with SNP genotype and did not materially affect the significance of any of the 6 reported associations (details not shown).

We used Haploview software v4.2 (<http://www.broadinstitute.org/haploview>) to infer the LD structure of the genome in the regions around *GREM1*, *BMP2* and *BMP4*. The combined effects of pairs of loci identified as associated with CRC risk were investigated by multiple logistic regression analysis in PLINK to test for independent effects of each SNP and stratifying by sample series. Evidence for interactive effects between SNPs (epistasis) was assessed by likelihood ratio test assuming an allelic model in PLINK.

The sibling relative risk attributable to a given SNP was calculated using the formulawhere *p* is the population frequency of the minor allele, *q* = 1−*p*, and *r* ~1~ and *r* ~2~ are the relative risks (estimated as OR) for heterozygotes and rare homozygotes, relative to common homozygotes [@pgen.1002105-Houlston3]. Assuming a multiplicative interaction, the proportion of the familial risk attributable to a SNP was calculated as log(λ^\*^)/log(λ~0~), where λ~0~ is the overall familial relative risk estimated from epidemiological studies of CRC, assumed to be 2.2 [@pgen.1002105-Johns1]. UK2/NSCCG2 samples were used for this estimation. The Akaike information criterion was calculated using the swaic command in STATA.

Genome co-ordinates were taken from the NCBI build 36/hg18 (dbSNP b126).

Supporting Information {#s5}
======================

###### 

Fine mapping around the known CRC risk SNPs close to (a) *BMP4* (14q22) and (b) *BMP2* (20p12).

(DOCX)

###### 

Click here for additional data file.

###### 

Pairwise linkage disequilibrium between rs4779584, rs16969681 and rs11632715 near *GREM1* (upper) and position of recombination hotspot (lower).

(DOCX)

###### 

Click here for additional data file.

###### 

Histone methylation and acetylation marks upstream of *GREM1*.

(DOCX)

###### 

Click here for additional data file.

###### 

Study design for discovery and validation phases.

(DOCX)

###### 

Click here for additional data file.

###### 

Large-scale LD structure in regions around *BMP4* and *BMP2*.

(DOCX)

###### 

Click here for additional data file.

###### 

Locations of recombination hotspots in regions around *BMP4* and *BMP2*.

(DOCX)

###### 

Click here for additional data file.

###### 

SNPs genotyped directly or predicted by imputation in the fine mapping of the regions around rs4779584, rs4444235, and rs961253 in UK2 and Scotland2.

(DOCX)

###### 

Click here for additional data file.

###### 

Haplotype risk analysis at rs16969681 and rs4779584.

(DOCX)

###### 

Click here for additional data file.

###### 

Logistic regression model analysis of CRC risk and genotypes at rs4779584, rs16969681, and rs11632715.

(DOCX)

###### 

Click here for additional data file.

###### 

TagSNPs around *GREM1*, *BMP4*, and *BMP2* analysed for new associations.

(DOCX)

###### 

Click here for additional data file.

###### 

Additional BMP pathway genes around which tagSNP associations with CRC were analysed.

(DOCX)

###### 

Click here for additional data file.

###### 

Consortium co-authors.

(DOCX)

###### 

Click here for additional data file.

This study made use of genotyping data on the 1958 Birth Cohort and NBS samples, kindly made available by the Investigators of those studies and the Wellcome Trust Case-Control Consortium 2; a full list of the investigators who contributed to the generation of the data is available from <http://www.wtccc.org.uk/>. Finally, we would like to thank all individuals who participated in the study.

The authors have declared that no competing interests exist.

Cancer Research UK provided principal funding for this study individually to IPM Tomlinson, MG Dunlop, RS Houlston, P Pharoah, and J Cheadle. Additional funding was provided by the Oxford Comprehensive Biomedical Research Centre (to IPM Tomlinson) and the EU FP7 CHIBCHA grant (to LG Carvajal-Carmona and IPM Tomlinson). Core infrastructure support to the Wellcome Trust Centre for Human Genetics, Oxford, was provided by grant 075491/Z/04. Additional funding (to MG Dunlop) was provided by the Medical Research Council (G0000657-53203), CORE, and Scottish Executive Chief Scientist\'s Office (K/OP/2/2/D333, CZB/4/449). The Colon Cancer Family Registry was supported by the National Cancer Institute, National Institutes of Health, under Request for Application \#CA-95-011, and through cooperative agreements with the Australian Colorectal Cancer Family Registry (UO1 CA097735), the USC Familial Colorectal Neoplasia Collaborative Group (UO1 CA074799), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (UO1 CA074800), Ontario Registry for Studies of Familial Colorectal Cancer (UO1 CA074783), Seattle Colorectal Cancer Family Registry (UO1 CA074794), and The University of Hawaii Colorectal Cancer Family Registry (UO1 CA074806). E Theodoratou was funded by a Cancer Research UK Fellowship (C31250/A10107). COIN and COIN-B were funded by the UK Medical Research Council. COIN sample analysis (J Cheadle) was also funded by Cancer Research Wales, Tenovus & Wales Gene Park. P Pharoah is a Cancer Research UK Senior Clinical Research Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[^1]: Conceived and designed the experiments: IPM Tomlinson, RS Houlston, MG Dunlop. Performed the experiments: LG Carvajal-Carmona, AM Jones, K Howarth, P Broderick, EEM Jaeger, S Farrington, A Lewis, JGD Pendergast, AM Pittman, B Olver, M Walker, N Whiffin, C Ruiz-Ponte, C Fernandez-Rozadilla. Analyzed the data: IPM Tomlinson, LG Carvajal-Carmona, SE Dobbins, A Tenesa, AM Jones, C Palles, E Theodoratou, S Ballereau, A Lloyd, J-B Cazier. Contributed reagents/materials/analysis tools: S Penegar, E Barclay, L Martin, M Gorman, S Lubbe, B Howie, J Marchini, A Castells, A Carracedo, S Castellvi-Bel, D Duggan, D Conti, H Campbell, O Sieber, L Lipton, P Gibbs, NG Martin, GW Montgomery, J Young, PN Baird, P Newcomb, J Hopper, MA Jenkins, LA Aaltonen, DJ Kerr, J Cheadle, P Pharoah, G Casey, S Gallinger. Wrote the paper: IPM Tomlinson, RS Houlston, MG Dunlop.

[^2]: ¶ Memberships of the consortia are provided in [Text S1](#pgen.1002105.s012){ref-type="supplementary-material"}.
